3Horan TC, Andrus M, Dudeck MA, et al. CDC/NHSN sur- veillance definition of healthcare-associated infection and crite- ria for specific types of infections in the acute care setting[J]. Am J Infect Control, 2008 , 36(5) :309- 332.
4Mermel LA, Allon M, Bouza E, et al. Clinical practice guide- lines for the diagnosis and management of intravascular cathe- ter-related infection: 2009 Update by the Infectious Diseases Society of America EJ]. Clin Infect Dis, 2009, 49(1) : 1 - 45.
5Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-re- sistant, extensively drug-resistant and pandrug-resistant bacte- ria: an international expert proposal for interim standard defi- nitions for acquired resistanceEJ]. Clin Microbiol Infect, 2012, 18(3) :268 - 281.
6O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections[J]. Am J Infect Control, 2011 , 39(4 Suppl 1) :$1 - 834.
7Siegel JD, Rhinehart E, Jackson M, et al. Management ofmultidrug-resistant organisms in health care settings, 2006 [J]. Am J Infect Control, 2007, 35(10 Suppl 2):S165 - S193.
8Dudeck MA, Weiner LM, Allen-Bridson K, et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, Device-associated module~J3. Am J Infect Control, 2013, 41(12):1148- 1166.
9Huskins WC, Huckabee CM, O'Grady NP, et al. Intervention to reduce transmission of resistant bacteria in intensive care [J3- N EnglJ Med, 2011,364(15): 1407-1418.
10Pires dos Santos R, Jacoby T, Pires Machado D, et al. Hand hygiene, and not ertapenem use, contributed to reduction of carbapenem-resistant Pseudomonas aeruginosa ratesCJ~. In- fect Control Hosp Epidemiol, 2011, 32(6) :584- 590.
